| A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma | A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma | NCT02146118 |
| Effects of Silybin in Hypertensive Patients | Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study | NCT03538327 |
| Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin | Prospective Double Arm Randomized Trial for Patients With Multiple Brain Metastasis and/or Leptomeningeal Carcinomatosis: Comparison of WBRT Alone and WBRT Plus Silibinin (Sillbrain) | NCT05793489 |
| Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients | Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients: a Multicenter, Double-blind, Placebo-controlled, Randomized Study | NCT06964815 |
| Silybin Supplementation During HCV Therapy With Pegylated Interferon-a2b Plus Ribavirin Reduces Depression and Increases Work Ability | Silybin Supplementation During HCV Therapy With Pegylated Interferon-a2b Plus Ribavirin Reduces Depression and Increases Work Ability | NCT01957319 |
| Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders | Multicenter Study To Evaluate The Efficacy Of Silymarin In Addition To Combination-Therapy With Pegylated Interferon Alfa 2a (Peg-Ifn Alfa 2a) And Ribavirin In Patients With Chronic Hepatitis C | NCT00684268 |
| Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning | A Phase II Multi-Center Open-Label Clinical Trial to Assess the Prevention of Liver Transplantation and/or Death Among Subjects Treated With Intravenous Silibinin (Legalon® SIL) for Amatoxin Induced Hepatic Failure | NCT00915681 |
| THISTLE - The HIV-HCV Silibinin Trial | A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS) | NCT01816490 |
| Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C | A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon® SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C | NCT01871662 |
| Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress | Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on High-Intensity Exercise-Induced Oxidative Stress: A Randomized, Crossover, Placebo-Controlled, Triple-Blind Study | NCT07024966 |
| Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard anti-HCV treatment. | Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interferon/ribavirin plus a protease inhibitor (triple therapy): a randomized, controlled, parallel-group, multicenter clinical trial. - Silibinin as an ANtiviral Treatment Enhancement to a standard antiviral combination therapy (SANTÉ) | EUCTR2013-000245-39-DE |
| High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety | High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety - HISTORY | EUCTR2012-004442-15-DE |
| Trial of Indole-3-Carbinol and Silibinin | Trial of Indole-3-Carbinol & Silibinin | NCT03687073 |
| Randomised clinical trial to test if silibinin administration can prevent the respiratory failure secondary to the COVID19 lung infection in oncologic patients. | Phase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infection by COVID-19 positive. - SilCOVID19 | EUCTR2020-001794-77-ES |
| Pilot study on silibinin as a possible therapeutic agent for mildly ill COVID-19 patients | Pilot study on silibinin as a possible therapeutic agent for mildly ill COVID-19 patients | EUCTR2020-005580-32-AT |
| Effect of Silibinin(A) as a Potential Anti-obesity Agent | Effect of Milk Thistle Derivative Silibinin(A) as a Potential Anti-obesity Agent | NCT05069298 |
| SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET) | A Phase 2 Randomized, Multicenter Trial on Silibinin To Prevent Intracranial Recurrence After Gross-Total Resection of Single Brain Metastasis From Non-Small Cell Lung Cancer or Breast Cancer | NCT05689619 |
| Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard anti-HCV treatment. | Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interferon/ribavirin plus a protease inhibitor (triple therapy): a randomized, controlled, parallel-group, multicenter clinical trial. - Silibinin as an ANtiviral Treatment Enhancement to a standard antiviral combination therapy (SANTÉ) | EUCTR2013-000245-39-AT |
| Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV | | NCT01935817 |
